3.4. Effects of BB536 Intake on DC Activity In Vivo
We detected that hk-BB536 showed stimulatory activity on pDCs in vitro. We evaluated DC activity, including the surface markers CD86 and HLA-DR, on pDCs and mDCs, respectively, in PBMCs before and after 4 weeks of BB536 administration in our randomized, double-blind, placebo-controlled clinical study. There were no significant differences between the BB536 and placebo groups at baseline for any of the markers. After the 4-week intervention, a significant increase in CD86 activity on pDCs was observed in the BB536 group (